Related references
Note: Only part of the references are listed.Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
Vikas Gupta et al.
BLOOD (2011)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation
Federica Sora et al.
LEUKEMIA RESEARCH (2011)
Will newer tyrosine kinase inhibitors have an impact in AML?
Mark J. Levis
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00
Renato Bassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation
Paul J. Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
Farhad Ravandi et al.
LEUKEMIA RESEARCH (2010)
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Stephan Metzelder et al.
BLOOD (2009)
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Rowan T. Chlebowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome
Claire Green et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
FLT3 internal tandem duplication during myelodysplastic syndrome follow-up:: a marker of transformation to acute myeloid leukemia
Ronald Feitosa Pinheiro et al.
CANCER GENETICS AND CYTOGENETICS (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML
Martin Bornhaeuser et al.
BLOOD (2007)
Correction of anemia with epoetin alfa in chronic kidney disease
Ajay K. Singh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML
Sohell Meshinchi et al.
BLOOD (2006)
Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations
M Griffiths et al.
LEUKEMIA (2005)
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML 10 and 12 trials
RE Gale et al.
BLOOD (2005)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3:: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells
E Sitnicka et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
PD Kottaridis et al.
BLOOD (2002)
Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy
P Bojko et al.
ANNALS OF HEMATOLOGY (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
SL Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
